Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by J. Safra Sarasin Holding AG

Key Points

• J. Safra Sarasin Holding AG reduced its stake in Alnylam Pharmaceuticals by 8.8%, selling 1,439 shares and holding 14,996 shares valued at approximately $4.89 million.
• Insider transactions indicate significant selling activity, with Director Colleen F. Reitan and Director Dennis A. Ausiello selling 18,000 and 31,448 shares respectively, which marked decreases in their holdings of over 95%.
• Alnylam Pharmaceuticals exceeded earnings expectations with a reported $0.32 EPS for the quarter, significantly higher than the consensus estimate of ($0.54) and showing a 17.3% year-over-year revenue increase.

J. Safra Sarasin Holding AG lessened its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 8.8% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 14,996 shares of the biopharmaceutical company's stock after selling 1,439 shares during the period. J. Safra Sarasin Holding AG's holdings in Alnylam Pharmaceuticals were worth $4,890,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also modified their holdings of ALNY. Vanguard Group Inc. increased its stake in shares of Alnylam Pharmaceuticals by 2.5% in the 1st quarter. Vanguard Group Inc. now owns 13,056,605 shares of the biopharmaceutical company's stock worth $3,525,544,000 after acquiring an additional 323,206 shares during the last quarter. T. Rowe Price Investment Management Inc. lifted its stake in Alnylam Pharmaceuticals by 0.8% during the first quarter. T. Rowe Price Investment Management Inc. now owns 4,418,145 shares of the biopharmaceutical company's stock worth $1,192,988,000 after purchasing an additional 33,696 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its stake in Alnylam Pharmaceuticals by 5.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,505,168 shares of the biopharmaceutical company's stock worth $946,466,000 after acquiring an additional 185,783 shares in the last quarter. American Century Companies Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 9.8% in the first quarter. American Century Companies Inc. now owns 1,760,435 shares of the biopharmaceutical company's stock valued at $475,353,000 after purchasing an additional 156,411 shares during the period. Finally, Orbis Allan Gray Ltd boosted its position in Alnylam Pharmaceuticals by 11.0% in the 1st quarter. Orbis Allan Gray Ltd now owns 1,634,923 shares of the biopharmaceutical company's stock valued at $441,462,000 after buying an additional 162,121 shares during the period. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, Director Colleen F. Reitan sold 18,000 shares of the firm's stock in a transaction dated Tuesday, September 9th. The shares were sold at an average price of $467.60, for a total transaction of $8,416,800.00. Following the completion of the transaction, the director directly owned 775 shares in the company, valued at approximately $362,390. This trade represents a 95.87% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Dennis A. Ausiello sold 31,448 shares of Alnylam Pharmaceuticals stock in a transaction dated Thursday, August 14th. The stock was sold at an average price of $436.58, for a total transaction of $13,729,567.84. Following the transaction, the director owned 911 shares of the company's stock, valued at approximately $397,724.38. The trade was a 97.18% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 75,594 shares of company stock valued at $33,968,256 in the last 90 days. 1.50% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the stock. Citigroup increased their price objective on shares of Alnylam Pharmaceuticals from $527.00 to $583.00 and gave the company a "buy" rating in a research report on Tuesday, September 2nd. Bank of America increased their target price on shares of Alnylam Pharmaceuticals from $453.00 to $520.00 and gave the company a "buy" rating in a research report on Wednesday, September 17th. Truist Financial began coverage on shares of Alnylam Pharmaceuticals in a research note on Monday, July 21st. They set a "buy" rating and a $385.00 price target on the stock. BMO Capital Markets upped their price objective on shares of Alnylam Pharmaceuticals from $450.00 to $470.00 and gave the company an "outperform" rating in a research note on Friday, September 5th. Finally, Piper Sandler lifted their target price on Alnylam Pharmaceuticals from $304.00 to $449.00 and gave the stock an "overweight" rating in a research report on Friday, August 1st. Twenty-four analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. Based on data from MarketBeat, Alnylam Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus price target of $439.58.

Alnylam Pharmaceuticals Trading Up 0.1%

NASDAQ:ALNY opened at $460.99 on Friday. Alnylam Pharmaceuticals, Inc. has a 12-month low of $205.87 and a 12-month high of $484.21. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 4.10. The stock's 50 day simple moving average is $439.02 and its 200-day simple moving average is $337.29. The firm has a market cap of $60.43 billion, a P/E ratio of -186.64 and a beta of 0.36.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, topping the consensus estimate of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The company had revenue of $773.69 million during the quarter, compared to analysts' expectations of $633.54 million. During the same quarter last year, the business earned ($0.13) EPS. The business's revenue was up 17.3% on a year-over-year basis. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.